Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption
Authors
Zhao, HaijunShi, Pengcheng
Deng, Manman
Jiang, Zhiwu
Li, Yin
Kannappan, Vinodh
Wang, Weiguang
Li, Peng
Xu, Bing
Issue Date
2016-11-19
Metadata
Show full item recordAbstract
Chemoresistance represents a major challenge for treatment of acute lymphoblastic leukemia (ALL). Thus, new drugs to overcome chemoresistance in ALL are urgently needed. To this end, we established a cytarabine (araC)-resistant ALL cell line (NALM-6/R), which interestingly displayed cross-resistance towards doxorubicin (ADM). Here we report that low dose of triptolide (TPL), a natural product used for treating inflammatory diseases such as arthritis, could reverse araC and ADM resistance and in NALM-6/R cells as well as primary cells from patients with relapsed or refractory (R/R) ALL, reflected by inhibition of cell proliferation and induction of apoptosis in vitro, and repression of tumor growth in vivo in a mouse xenograft model. Mechanistically, these events were associated with impaired mitochondrial membrane potential and increased reactive oxygen species (ROS) production. Co-treatment with TPL and araC or ADM upregulated pro-apoptotic caspase-9 protein, inhibited checkpoint kinase 1 (Chk1) and 2 (Chk2) phosphorylation, and induced γH2A.X (a DNA damage marker). Notably, the combination regimen of TPL and conventional chemotherapeutics also rapidly diminished tumor burden in a patient with R/R ALL. Together, these findings provide preclinical evidence for repurposing use of TPL in combination with chemotherapeutic agents to treat R/R ALL as an alternative salvage regimen.Citation
Zhao H., Shi P., Deng M., Jiang Z., Li, Y., Kannappan V., Wang W., Li P., Xu B. (2016) 'Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption' Oncotarget, 7 (51) pp. 85515-85528. doi: 10.18632/oncotarget.13454.Publisher
ElsevierJournal
OncotargetAdditional Links
http://www.oncotarget.com/abstract/13454Type
Journal articleLanguage
enISSN
1949-2553ae974a485f413a2113503eed53cd6c53
10.18632/oncotarget.13454
Scopus Count
Collections
The following licence applies to the copyright and re-use of this item:
- Creative Commons
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/3.0/